Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
OBJECTIVE
In heart failure atrial natriuretic peptide (ANP) release in response to volume expansion is impaired while the renin-angiotensin system is activated. This study was designed to test the hypothesis that ANP release in heart failure is dependent on an activated angiotensin system.


METHODS
We studied the ANP and renin-angiotensin systems in a rat model of shunt-induced high-output heart failure, in which we rapidly increased circulating fluid volume with a 5 ml, hyperoncotic infusion, and evaluated the effects of acute inhibition of the angiotensin converting enzyme as well as of the blockade of the angiotensin II type 1 receptors on the ANP release and on renal excretory function.


RESULTS
ANP and angiotensin II plasma concentrations prior to volume expansion were elevated (p < 0.05) in rats with aortocaval shunt compared to controls. The diuretic response to acute volume expansion (18.5 +/- 1.5 vs. 48.2 +/- 2.4 microliters/min, p < 0.001) was markedly blunted. ANP release was attenuated in rats with aortocaval shunt, as was the increase of its second messenger cGMP in plasma and urine. The blunted increase in ANP plasma levels was not due to depleted cardiac stores as cardiac ANP content, as well as ANP synthesis, were increased (p < 0.05). Acute inhibition of the angiotensin converting enzyme as well as blockade of the angiotensin II type 1 receptors restored ANP release in response to volume expansion (p < 0.01). Moreover, acute inhibition of the renin-angiotensin system completely normalized the diuretic response.


CONCLUSIONS
Our data suggest that the ANP system is impaired in rats with aortocaval shunt. The activation of the angiotensin system contributes to the impairment of the ANP system. Acute inhibition of the angiotensin II system significantly improved the ability of the ANP system to respond to acute volume expansion. Our findings indicate a hitherto fore unappreciated interaction between both systems and suggest additional mechanisms for the beneficial effects of angiotensin converting enzyme inhibition or angiotensin II type 1 receptor antagonists in heart failure.
Willenbrock
R
R
Franz Volhard Clinic, Max Delbrück Center for Molecular Medicine, University Hospital Charité, Humboldt University of Berlin, Germany.
Scheuermann
M
M
Thibault
G
G
Haass
M
M
Höhnel
K
K
Bohlender
J
J
Luft
F C
FC
Dietz
R
R
D000804:Angiotensin II / Q000097:blood*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000096:biosynthesis / Q000097:blood*; D001810:Blood Volume; D006152:Cyclic GMP / Q000097:blood / Q000652:urine; D004231:Diuresis; D006333:Heart Failure / Q000097:blood / Q000503:physiopathology* / Q000652:urine; D008297:Male; D009206:Myocardium / Q000378:metabolism; D017257:Ramipril / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012084:Renin-Angiotensin System; D018709:Statistics, Nonparametric; D013777:Tetrazoles / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology; D000068756:Valsartan
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D013777:Tetrazoles; D000804:Angiotensin II; C052549:ramiprilat; D000068756:Valsartan; D009320:Atrial Natriuretic Factor; D006152:Cyclic GMP; D014633:Valine; D017257:Ramipril